Gilead Sciences, Inc. (NASDAQ:GILD) Stock Holdings Lowered by Atria Wealth Solutions Inc.

Atria Wealth Solutions Inc. lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 58,461 shares of the biopharmaceutical company’s stock after selling 2,703 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in Gilead Sciences were worth $5,400,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Bellevue Group AG raised its holdings in shares of Gilead Sciences by 18.2% during the third quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company’s stock valued at $3,859,000 after acquiring an additional 7,093 shares during the period. Quantinno Capital Management LP raised its holdings in shares of Gilead Sciences by 149.5% during the third quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company’s stock valued at $6,843,000 after acquiring an additional 48,910 shares during the period. McAdam LLC raised its holdings in shares of Gilead Sciences by 16.7% during the fourth quarter. McAdam LLC now owns 25,372 shares of the biopharmaceutical company’s stock valued at $2,344,000 after acquiring an additional 3,627 shares during the period. IRON Financial LLC acquired a new stake in shares of Gilead Sciences during the third quarter valued at approximately $830,000. Finally, Capital Investment Advisors LLC raised its holdings in shares of Gilead Sciences by 2.6% during the fourth quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company’s stock valued at $35,793,000 after acquiring an additional 9,791 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $104.09, for a total value of $260,225.00. Following the completion of the transaction, the chief financial officer now owns 169,061 shares of the company’s stock, valued at $17,597,559.49. This represents a 1.46 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jeffrey Bluestone sold 6,788 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the transaction, the director now directly owns 8,920 shares of the company’s stock, valued at approximately $815,198.80. This trade represents a 43.21 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 713,000 shares of company stock valued at $67,945,181 in the last quarter. Corporate insiders own 0.29% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on GILD shares. Citigroup started coverage on shares of Gilead Sciences in a research report on Thursday, November 14th. They set a “buy” rating and a $125.00 price objective on the stock. Mizuho boosted their price objective on shares of Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a research report on Thursday, November 21st. Piper Sandler boosted their price objective on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday, February 12th. Barclays boosted their price objective on shares of Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a research report on Thursday, November 7th. Finally, Oppenheimer boosted their price objective on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. Eleven analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $102.08.

Gilead Sciences Price Performance

NASDAQ GILD opened at $107.65 on Thursday. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $107.81. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The stock has a market capitalization of $134.16 billion, a PE ratio of 290.95, a P/E/G ratio of 0.87 and a beta of 0.18. The stock has a 50-day simple moving average of $94.70 and a 200 day simple moving average of $88.23.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Research analysts anticipate that Gilead Sciences, Inc. will post 7.94 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be issued a $0.79 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. This represents a $3.16 annualized dividend and a yield of 2.94%. Gilead Sciences’s dividend payout ratio is 832.43%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.